STANFORD, CA – April 24, 2024 – A scientific revelation, published today in the prestigious journal Science, has dramatically reshaped our understanding of the immune system’s intricate dance with cancer. Researchers at Stanford Medicine have uncovered a surprising, critical role for erythropoietin (EPO)—a protein identified nearly four decades ago for its primary function in stimulating red blood cell production—as a potent dampener of the body’s anti-cancer immune response. This groundbreaking discovery offers a powerful new strategy to transform notoriously "cold," immune-resistant tumors into "hot" battlegrounds teeming with cancer-fighting cells, potentially revolutionizing treatment for a wide array of human cancers.
The study, led by Edgar Engleman, MD, PhD, a professor of pathology and of medicine, and basic life research scientist David Kung-Chun Chiu, PhD, demonstrates that blocking EPO’s activity can effectively reprogram the tumor microenvironment. In mouse models of liver cancer, this intervention turned previously unresponsive tumors into targets highly susceptible to immunotherapy. When combined with existing immune-activating therapies, the treatment achieved complete regression of established liver tumors in the majority of mice, allowing them to live for the entire duration of the experiment, a stark contrast to control animals who succumbed within weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," Dr. Engleman stated, his excitement palpable. "I could not be more thrilled about this discovery, and my hope is that treatments targeting this newly uncovered mechanism will swiftly advance to human trials."
Unraveling a Decades-Old Paradox: EPO’s Dual Nature
For nearly 40 years, erythropoietin has been celebrated for its vital role in hematopoiesis, the process of forming red blood cells. Its therapeutic application in treating anemia, particularly in patients with kidney disease or undergoing chemotherapy, has been well-established. However, EPO has also carried a lingering, troubling shadow within oncology.
A Troubling Historical Precedent
The initial hints of EPO’s detrimental connection to cancer emerged more than a decade ago. Clinical observations revealed a perplexing and alarming trend: when anemic cancer patients were administered exogenous EPO to stimulate red blood cell formation, their tumors often exhibited accelerated growth. This correlation was so striking and concerning that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box warning" label on EPO-stimulating drugs, cautioning against their use in individuals with cancer.
Further research at the time also established a clear, albeit unexplained, correlation between naturally occurring levels of EPO and its receptor (EPOR) within tumors and a patient’s prognosis. "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman explained. "But the crucial connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, precisely because EPO is so well established as a red blood cell growth factor." The scientific community, including Dr. Engleman himself, had been tethered to EPO’s established identity, overlooking its potential clandestine operations within the complex tumor microenvironment.
The Genesis of the Discovery: Chasing Immune Resistance
The journey to this pivotal discovery began with Dr. David Kung-Chun Chiu’s meticulous work in developing sophisticated genome-editing techniques. Dr. Chiu created several highly representative mouse models of liver cancer, each designed to recapitulate specific genetic mutations, histological features, and responses to approved therapies found in various subtypes of human liver cancers. Tumor formation was induced either by injecting a combination of DNA encoding liver cancer-associated proteins into the animals’ tail veins or by directly implanting liver cancer cells into their livers. These models provided an invaluable platform to dissect the intricate mechanisms of tumor development and therapeutic response.
The initial focus of the research team was on understanding the efficacy of a common and transformative immunotherapy: checkpoint blockade targeting the programmed cell death protein 1 (PD-1) on immune cells, specifically T cells. Anti-PD-1 therapies, such as the commercially available Keytruda, work by liberating T cells from the suppressive grip of cancer cells, allowing them to mount an attack. While these therapies have achieved remarkable successes in certain cancers like melanoma, Hodgkin’s lymphoma, and some types of lung cancer, transforming patient outcomes, a vast majority of tumors—including prevalent types like liver, pancreas, colon, breast, and prostate cancers—remain stubbornly resistant. These resistant tumors are often termed "cold" tumors due to their lack of immune cell infiltration.
The researchers observed a phenomenon in their mouse models mirroring human liver cancers: certain combinations of genetic mutations led to the development of "cold" liver tumors that were largely ignored by the immune system. These immune-privileged tumors exhibited minimal T-cell infiltration and, consequently, showed no response to anti-PD-1 treatment. In stark contrast, other genetic mutations resulted in "hot" or "inflamed" tumors, replete with an abundance of T cells. These "hot" tumors were highly sensitive to anti-PD-1 therapy, which effectively unleashed the T cells to aggressively attack and shrink the cancer.
The Unexpected Link: Hypoxia and Elevated EPO
It was during this comparative analysis that the unexpected link emerged. The "cold" tumors consistently displayed significantly elevated levels of EPO compared to their "hot" counterparts. This increase, the researchers theorized, was likely driven by the oxygen-poor microenvironment—a condition known as hypoxia—that is prevalent within many rapidly growing, poorly vascularized tumors, particularly "cold" ones. Hypoxia is a well-known inducer of specific proteins in cancer cells, which, in turn, ramp up the production of EPO in an attempt to combat low oxygen levels by stimulating more red blood cell formation.
"Hypoxia in tumors has been studied for decades," Dr. Engleman noted, reflecting on the missed connection. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." The established paradigm had, for too long, limited scientific inquiry into EPO’s broader biological functions within the tumor landscape.
Decoding the Mechanism: EPO as an Immunosuppressive Maestro
To validate their hypothesis and delve deeper into the mechanism, the researchers first turned to existing public databases. Their analysis confirmed a compelling correlation: elevated levels of EPO were indeed linked to poorer survival outcomes in human patients across a range of cancers, including those of the liver, kidney, breast, colon, and skin. This critical epidemiological data strongly suggested that the observations in mice were highly relevant to human disease.
Experimental Confirmation and Mechanistic Elucidation
The next step involved direct manipulation of EPO production within the tumor cells themselves. The results were startling and definitive:
- When "cold" tumors, initially developed from specific mutations, were genetically modified to be incapable of producing EPO, they transformed into "hot" tumors, now infiltrated with T cells.
- Conversely, "hot" tumors that had previously been successfully eradicated by the immune system thrived and grew unchecked when they were engineered to produce elevated levels of EPO.
These experiments provided incontrovertible evidence that EPO was not merely a bystander or a consequence of the tumor microenvironment, but an active, instrumental player in shaping the immune response.
Through further exhaustive research, the team meticulously unraveled the precise cellular and molecular crosstalk mediated by EPO. They discovered that within "cold" tumors, the cancer cells themselves produce and secrete EPO. This secreted EPO then acts as a signaling molecule, binding to its specific receptors (EPOR) located on the surface of nearby immune cells called macrophages. Upon binding, EPO triggers a phenotypic switch in these macrophages, compelling them to adopt an immunosuppressive role. In this altered state, these macrophages actively deter the infiltration of cancer-killing T cells into the tumor and, simultaneously, tamp down the activity of any T cells that manage to gain entry. Essentially, EPO orchestrates a hostile takeover of the tumor microenvironment, creating an immune desert where T cells cannot thrive or function.
The Power of Combination Therapy
The profound importance of this EPO-moderated crosstalk between tumor cells and macrophages became unequivocally clear when the researchers investigated the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway.
In these pivotal experiments, mice bearing "cold" liver tumors that received either a control treatment or anti-PD-1 monotherapy showed dismal outcomes, with none surviving beyond eight weeks after tumor induction. This starkly highlighted the inherent resistance of "cold" tumors to conventional immunotherapy.
However, a dramatic shift occurred when the EPO signaling pathway was disrupted. In mice whose macrophages were genetically engineered to be unable to express the EPO receptor, thus rendering them unresponsive to tumor-derived EPO, a significant improvement in survival was observed: 40% of these animals lived for the full 18-week duration of the experiment, at which point it was terminated.
The most compelling outcome, demonstrating a powerful synergistic effect, came when anti-PD-1 treatment was administered to mice that also lacked the EPO receptor on their macrophages. In this combined therapeutic approach, a remarkable all of the animals survived for the entire duration of the experiment. This near-complete eradication of established "cold" tumors underscored the potential of simultaneously disarming EPO’s immunosuppressive influence while unleashing the T-cell response.
"It’s simple," Dr. Engleman concluded, summarizing the elegant power of the discovery. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment."
Broader Implications and Future Horizons
This groundbreaking research carries immense implications for the future of cancer therapy, particularly for patients battling cancers currently resistant to existing immunotherapies.
Applicability Across Many Cancers
Although the meticulous work was conducted in mouse models of liver cancer, the researchers have strong indications that EPO plays a similar immunosuppressive role in a wide variety of human cancers. The correlation between elevated EPO levels and poorer patient survival, observed in databases for cancers of the liver, kidney, breast, colon, and skin, suggests a broadly conserved mechanism. This broad applicability opens the door for potentially transforming treatment paradigms for a significant proportion of cancer patients worldwide.
Developing New Therapeutic Strategies
Armed with this newfound understanding, Dr. Engleman and his colleagues are now actively designing and developing novel therapeutic strategies specifically targeting EPO signaling in human cancers. Several approaches are being considered:
- Non-specific targeting of the EPO protein: This strategy would aim to reduce overall EPO levels in the body. While potentially effective, Dr. Engleman acknowledges a potential trade-off: a reduction in EPO could lead to anemia, given the protein’s primary role in red blood cell production. However, he speculates that for an effective cancer therapy, this might be an "acceptable trade-off" for patients facing life-threatening disease.
- Selective blocking of EPO receptors on macrophages: This more targeted approach would aim to specifically neutralize EPO’s immunosuppressive effects within the tumor microenvironment without interfering with its systemic role in red blood cell formation. This strategy holds the promise of fewer systemic side effects, potentially offering a more refined and tolerable treatment option.
The ability to reprogram the tumor microenvironment, turning "cold" tumors "hot," represents a significant leap forward. Many solid tumors, including pancreatic, colorectal, and prostate cancers, are notoriously "cold" and have largely been unresponsive to current checkpoint blockade immunotherapies. This discovery provides a novel avenue to potentially render these resistant cancers susceptible to existing powerful immunotherapies, thereby expanding the reach and efficacy of these life-saving treatments.
Re-evaluating a Well-Known Molecule
The findings also highlight the complexity of biological systems and the need for continuous re-evaluation of established scientific dogma. A molecule as well-studied as EPO, with a seemingly clear and singular primary function, has now revealed a hidden, critical role that profoundly impacts disease progression. This underscores the importance of persistent scientific inquiry and the courage to challenge long-held assumptions.
While the path from mouse studies to human clinical trials is often long and fraught with challenges, the robust nature of these findings, coupled with the existing clinical data on EPO’s negative impact in cancer, provides a strong impetus for rapid translation. The enthusiasm from Dr. Engleman is palpable: "I continue to be amazed by this finding. Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies."
This research was a collaborative effort, with contributions from researchers at the New York Blood Center and the pharmaceutical company ImmunEdge Inc. The study received vital financial support from the National Institutes of Health (grants R01CA262361, P01CA244114, U54CA2745115, and P01HL149626). Notably, Dr. Chiu is a cofounder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of the company. Both Dr. Chiu and Dr. Engleman are Stanford-affiliated inventors of a patent application (PCT/US2023/063997) titled "EPO receptor agonists and antagonists," indicating a clear path toward commercial development of these promising therapeutic strategies.
The journey from a historical paradox to a fundamental breakthrough, illuminating EPO’s unexpected role as an immune system suppressor in cancer, marks a pivotal moment in oncology research. It offers a renewed sense of hope that many cancers, once deemed untreatable by immunotherapy, may soon face a formidable new challenge.
About the Author
